MT Newswires Live04:22
Avalo Therapeutics (AVTX) on Friday filed a registration statement with the US Securities and Exchange Commission saying that some shareholders may from time to time sell up to 128,189 of its shares.
The company said it will not receive any proceeds from the proposed sale.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
